Gilead and Galapagos close in on filing for Xeljanz rival

In FINCH 1, selective JAK1 inhibitor filgotinib was compared to AbbVie’s $18bn-a-year TNF antibody Humira (adalimumab) or placebo – given on top of generic disease-modifying antirheumatic drug (DMARD) ... of Humira which is given by injection.

Takeda’s Entyvio tops Humira in ulcerative colitis

Entyvio is important for post-merger Takeda. Takeda’s key growth product Entyvio has outperformed AbbVie’s Humira in a trial in ulcerative colitis (UC), said to be the first ... The VARSITY study pitted anti-integrin antibody Entyvio (vedolizumab)

AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod

Johnson’s Stelara (targeting IL-23 and IL-12) and AbbVie’s own ageing market leader Humira. ... The launch of Skyrizi in Europe is especially important for AbbVie as Humira is already losing revenue rapidly in the continent thanks to the arrival late

UCB looks to pipeline with five years left for twin blockbusters

The company’s phase 3 study (NCT03412747) is a three-arm study of bimekizumab, Humira and placebo, with data expected in the first half of 2019.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]